Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The registered capital of the newly founded company is € 50 million
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
An accomplished R&D leader and champion of the application of AI to drug discovery
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Subscribe To Our Newsletter & Stay Updated